Pharmaceutical giant GlaxoSmithKline reported a 5 percent drop in global sales for the third quarter and said it will continue reducing its operating costs.
Affirming its commitment to investors, GSK boosted its dividend by 6 percent.
Sales dipped to $10.3 billion after adjusting for currency fluctuations, the London-based company said Wednesday. Operating profit totaled just over $2.6 billion, down 18 percent. The figures were reported in British pounds and converted to U.S. dollars.
GSK said European markets are especially challenging but the company has plenty of momentum in developing countries, especially for its vaccine lines.